{"id":"W4280541127","doi":"10.1136/jitc-2021-004076","title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Cilag; Foundation Medicine; Takeda Oncology; Chugai Pharmaceutical; Novartis Pharma; Genentech; Daiichi Sankyo Europe; National Cancer Institute; Servier; Eisai; Basilea Pharmaceutica; AstraZeneca; Institut National Du Cancer; Seagen; Agios Pharmaceuticals; Eisai Canada; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Boston Pharmaceuticals; Taiho Pharmaceutical; F. Hoffmann-La Roche; Yale University; Bayer HealthCare; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atezolizumab; Blockade; Solid tumor; Medicine; Immune checkpoint; Immune system; Oncology; Cancer research; Internal medicine; Immunology; Immunotherapy; Pembrolizumab; Cancer; Receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006289083,0.0003595008,0.001002939,0.0005488593,0.0003274417,0.00004152631,0.0003299288,0.00008301668,0.0004583306],"category_scores_gemma":[0.00005475037,0.0002807076,0.0003748511,0.000692623,0.0001418661,0.0003227,0.00003547313,0.000454386,2.553597e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001877718,"about_ca_system_score_gemma":0.001124437,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003946761,"about_ca_topic_score_gemma":0.0001217905,"domain_scores_codex":[0.9969502,0.00007462144,0.00133763,0.000382468,0.0006521847,0.0006028981],"domain_scores_gemma":[0.9981076,0.0001013854,0.001019155,0.0003145082,0.0003818225,0.00007549689],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.2331941,0.003375557,0.01682321,0.0004499041,0.0008348254,0.00005359176,0.01022837,0.00308418,0.6592176,0.00002942755,0.0001157762,0.07259351],"study_design_scores_gemma":[0.2266771,0.02297205,0.251354,0.002261552,0.0001337092,0.0003406808,0.006815892,0.0008919504,0.4687037,0.0004722082,0.01829544,0.00108172],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901083,0.00480001,0.0002742586,0.0009244584,0.000990004,0.002750743,0.0001038205,0.00002166929,0.00002681394],"genre_scores_gemma":[0.9946082,0.002087137,0.001027055,0.0004440364,0.00007301005,0.001382609,0.00004527125,0.0001015067,0.0002312357],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2345308,"threshold_uncertainty_score":0.9999645,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01447742620359424,"score_gpt":0.325284274372232,"score_spread":0.3108068481686377,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}